학술논문

Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies
Document Type
article
Source
American Journal of Epidemiology. 185(1)
Subject
Epidemiology
Health Sciences
Rare Diseases
Clinical Research
Human Genome
Prevention
Ovarian Cancer
Genetics
Cancer
Carcinoma
Ovarian Epithelial
Case-Control Studies
Comorbidity
Contraceptives
Oral
Hormonal
Family Health
Female
Genetic Predisposition to Disease
Hormone Replacement Therapy
Humans
Hysterectomy
Neoplasms
Glandular and Epithelial
Ovarian Neoplasms
Pelvic Inflammatory Disease
Protective Factors
Reproductive History
Risk Factors
Sterilization
Tubal
Talc
inflammation
neoplasms
histological type
ovarian neoplasms
pelvic inflammatory disease
risk factors
on behalf of the Ovarian Cancer Association Consortium
neoplasms
histological type
Mathematical Sciences
Medical and Health Sciences
Language
Abstract
Inflammation has been implicated in ovarian carcinogenesis. However, studies investigating the association between pelvic inflammatory disease (PID) and ovarian cancer risk are few and inconsistent. We investigated the association between PID and the risk of epithelial ovarian cancer according to tumor behavior and histotype. We pooled data from 13 case-control studies, conducted between 1989 and 2009, from the Ovarian Cancer Association Consortium (OCAC), including 9,162 women with ovarian cancers, 2,354 women with borderline tumors, and 14,736 control participants. Study-specific odds ratios were estimated and subsequently combined into a pooled odds ratio using a random-effects model. A history of PID was associated with an increased risk of borderline tumors (pooled odds ratio (pOR) = 1.32, 95% confidence interval (CI): 1.10, 1.58). Women with at least 2 episodes of PID had a 2-fold increased risk of borderline tumors (pOR = 2.14, 95% CI: 1.08, 4.24). No association was observed between PID and ovarian cancer risk overall (pOR = 0.99, 95% CI: 0.83, 1.19); however, a statistically nonsignificantly increased risk of low-grade serous tumors (pOR = 1.48, 95% CI: 0.92, 2.38) was noted. In conclusion, PID was associated with an increased risk of borderline ovarian tumors, particularly among women who had had multiple episodes of PID. Although our results indicated a histotype-specific association with PID, the association of PID with ovarian cancer risk is still somewhat uncertain and requires further investigation.